LDL-Cholesterol in secondary prevention: Goal-attainment in patients on lipid-lowering drugs in private practice and in hospitals in Austria (ZIEL);LDL-Cholesterin in der Sekundärprävention: Zielwert-Erreichung unter Lipidsenkern in Praxis und Spital in Österreich (ZIEL)

Wiener Klinische Wochenschrift

Volumn 123, Issue 1-2, 2011, Pages 21-27

  Föger, Bernhard ^a   Patsch, Josef R ^b  

^a Abteilung fur Innere Medizin   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Arteriosclerosis; Diabetes mellitus; Hyperlipidemia; LDL cholesterol; Statins

Indexed keywords

ANTILIPEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROSIS; AUSTRIA; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GOAL ATTAINMENT; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIVATE PRACTICE; SECONDARY PREVENTION;

AGED; ATHEROSCLEROSIS; AUSTRIA; CHOLESTEROL, LDL; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; HOSPITALIZATION; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; MALE; PREVALENCE; PRIVATE PRACTICE; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 79952282260     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-010-1498-7     Document Type: Article

References (10)

1. EUROASPIRE I and II Group 2001 Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries Lancet 357 995 1001 10.1016/S0140-6736(00)04235-5 (Pubitemid 32285391)
2. K Kotseva D Wood G De Backer D De Bacquer K Pyörälä U Keil for the EUROASPIRE Study Group 2009 Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III in eight European countries Lancet 373 929 940 10.1016/S0140-6736(09)60330-5 19286092
3. M Roden K Huber für die HSP-Projektgruppe 2008 Lipidprofil und Therapiestatus in der Sekundärprävention bei Hochrisiko-Patienten mit klinisch manifester Arteriosklerose und/oder Diabetes mellitus: Das Hospital Screening Projekt (HSP) in Österreich Wien Klin Wochenschr 120 558 565 10.1007/s00508-008-1010-9 18988009
4. SM Grundy JI Cleeman CNB Merz HB Brewer Jr LT Clark DB Hunninghake, et al. 2004 Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Circulation 110 227 239 10.1161/01.CIR.0000133317.49796.0E 15249516 (Pubitemid 38924592)
5. Patsch JR, Föger B. AAS Cholesterinkonsensus 2006. www.aas.at/aktuelles
6. WC Winkelmayer AE Bucsics A Schautzer P Wieninger M Pogantsch Pharmaeconomics Advisory Council of the Austrian Sickness Funds 2008 Use of recommended medications after myocardial infarction in Austria Eur J Epidemiol 23 153 162 10.1007/s10654-007-9212-4 18064529
7. M Pichler B Eber KP Pfeiffer H Toplak 2006 ACT-Studie: Therapieziele verfehlt Österr Ärztezeitung 19 60 65
8. C Baigent A Keech PM Kearney L Blackwell G Buck C Pollicino, et al. 2005 Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 1267 1278 1:CAS:528:DC%2BD2MXhtVOlu7fM 10.1016/S0140-6736(05)67394-1 16214597 (Pubitemid 41416582)
9. JC LaRosa SM Grundy DD Waters C Shear P Barter JC Fruchart, et al. 2005 Intensive lipid lowering with atorvastatin in patients with stable coronary disease NEJM 352 1425 1435 1:CAS:528:DC%2BD2MXjtVWltrw%3D 10.1056/NEJMoa050461 15755765 (Pubitemid 40471450)
10. TR Pedersen O Faergeman JJP Kastelein AG Olsson MJ Tikkanen I Holme, et al. 2005 High-dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction JAMA 294 2437 2445 1:CAS:528: DC%2BD2MXht1aku7jK 10.1001/jama.294.19.2437 16287954 (Pubitemid 41627921)